Jamieson Wellness Inc. announced today the appointment of Tania M. Clarke, Senior Vice-President and Chief Financial Officer of New Look Vision Group Inc., to the Company’s Board of Directors. “I am very pleased to welcome Ms. Clarke to our Board of Directors,” said David Williams, Chairman of the Board. “Ms. Clarke’s strong financial acumen coupled with her global consumer and retail experience will be ...

Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX: JWEL), announced today the appointment of Tania M. Clarke, Senior Vice-President and Chief Financial Officer of New Look Vision Group Inc., to the Company's Board of Directors.

"I am very pleased to welcome Ms. Clarke to our Board of Directors," said David Williams, Chairman of the Board. "Ms. Clarke's strong financial acumen coupled with her global consumer and retail experience will be invaluable as we continue to expand our reach to consumers around the world. Based in Montreal, Ms. Clarke will also provide more local perspective to support our continued growth in Canada and specifically the Quebec market."

Ms. Clarke is a senior financial executive with both public and private company experience across several industries including retail, food and beverage, and financial. Prior to joining New Look Vision Group, she served for three years as Chief Financial Officer of Imvescor Restaurant Group Inc. Ms. Clarke was also Chief Financial Officer and Acting Chief Information Officer at Le Groupe Voyage Vision 2000 Inc. from 2007 to 2010 and spent 14 years as Executive Vice-President and Chief Finance Officer at Grand Toys International Ltd.

Ms. Clarke is a Chartered Professional Accountant (CPA, CA) and a Certified Public Accountant (CPA-US). She sits on the Board of Directors of Futurepreneur, a non-profit organization, and was appointed to the Board of Directors of the Business Development Bank of Canada in June 2021.

"I am deeply honoured and proud to be joining the Jamieson team as a Board member," said Ms. Clarke. "Jamieson Wellness is a Canadian success story with longevity and strong results. I look forward to working with my fellow Board members and management to contribute to the Company's long-term growth strategy."

About Jamieson Wellness Inc.

Jamieson Wellness is dedicated to improving the world's health and wellness with its portfolio of innovative natural health brands. Established in 1922, Jamieson is the Company's heritage brand and Canada's #1 consumer health brand. Jamieson Wellness manufactures and markets sports nutrition products and specialty supplements under its Progressive, Precision and Iron Vegan brands. The Company also markets Smart Solutions, the #1 women's natural health focused brand in Canada. For more information please visit jamiesonwellness.com.

Forward-Looking Information

This press release may contain forward-looking information within the meaning of applicable securities legislation. Such information includes, but is not limited to, statements related to the Company's future plans, goals, strategies, intentions, beliefs, objectives, economic performance or expectations. Words such as "expect", "anticipate", "intend", "may", "will", "estimate" and variations of such words and similar expressions are intended to identify such forward-looking information. This information reflects the Company's current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company's control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to, the factors discussed under "Risk Factors" in the Company's Annual Information Form dated March 30, 2021 and under the "Risk Factors" section in the Company's MD&A dated November 3, 2021. This information is based on the Company's reasonable assumptions and beliefs in light of the information currently available to it and the statements are made as of the date of this press release. The Company does not undertake any obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law or regulatory authority.

The Company cautions that the list of risk factors and uncertainties is not exhaustive and other factors could also adversely affect the Company's results. Readers are urged to consider the risks, uncertainties and assumptions associated with these statements carefully in evaluating the forward-looking information and are cautioned not to place undue reliance on such information. See "Forward-looking Information" and "Risk Factors" within the Company's MD&A for a discussion of the uncertainties, risks and assumptions associated with these statements.

Investor and Media Contact:

Ruth Winker
Jamieson Wellness
416-705-5437
rwinker@jamiesonlabs.com

News Provided by Business Wire via QuoteMedia

Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today provided an update on the MOVe-OUT study of molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine for COVID-19. Data are now available from all enrolled participants (n=1433). In this study population, molnupiravir reduced the risk of hospitalization or death from 9.7% in the placebo group (68/699) to 6.8% (48/709) in the molnupiravir group, for an absolute risk reduction of 3.0% (95% confidence interval [CI]: 0.1, 5.9; nominal p-value=0.0218) and a relative risk reduction of 30% (relative risk 0.70; 95% CI: 0.49, 0.99). Nine deaths were reported in the placebo group, and one in the molnupiravir group. The adverse event profile for molnupiravir remained consistent with the profile reported at the planned interim analysis.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211126005279/en/

Keep reading... Show less

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Bob Smith, Vice President, Pfizer Rare Disease, at the 4th Annual Evercore ISI HealthCONx Conference on Wednesday, December 1, 2021 at 5:10 p.m. Eastern Standard Time.

To view and listen to the webcast, visit our web site at www.pfizer.com/investors . Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today.

Keep reading... Show less

Merck to Present at the 4th Annual Evercore ISI HealthCONx Conference

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Frank Clyburn, executive vice president and president of Human Health, is scheduled to participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on December 1, 2021 at 10:30 a.m. ET.

Investors, analysts, members of the media and the general public are invited to watch a live video webcast of the presentations at https://investors.merck.com/events-and-presentations/default.aspx .

Keep reading... Show less

Health Canada Approves KEYTRUDA® in Combination with Chemotherapy for the Treatment of Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1

Conditional Approval Based on Data from Phase 3 KEYNOTE-355 Trial; Introduces First Breast Cancer Indication for KEYTRUDA ®

Merck (NYSE: MRK), known as MSD outside the United States and Canada today announced that Health Canada has granted conditional approval for KEYTRUDA ® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with chemotherapy for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) in adults whose tumors express PD-L1 (Combined Positive Score [CPS] ≥10) and who have not received prior chemotherapy for metastatic disease. 1 This conditional approval is based on the results of the pivotal Phase 3 KEYNOTE-355 trial which demonstrated KEYTRUDA ® 's ability to improve progression-free survival (PFS) in combination with chemotherapy (nab-paclitaxel, paclitaxel or gemcitabinecarboplatin), as compared to chemotherapy alone. 2

Keep reading... Show less
Love Pharma Signs Letter of Intent to Acquire 100% Interest in MicrDoz Therapy Inc. To Expedite Pilot Study of Psilocybin Assisted Treatment of Cannabis Use Disorder with World Leading University

Love Pharma Signs Letter of Intent to Acquire 100% Interest in MicrDoz Therapy Inc. To Expedite Pilot Study of Psilocybin Assisted Treatment of Cannabis Use Disorder with World Leading University

Love Pharma Inc. ("LOVE" and or the "Company") (CSE:LUV) (FSE:G1Q0), is pleased to announce that it has executed a Letter of Intent ("LOI") to acquire 100% of MicroDoz Therapy Inc. ("MicroDoz"), which has an exclusive partnership and license with a world leading university to conduct a landmark study into the efficacy of psilocybin assisted treatment of cannabis use disorder. Upon the closing of the definitive agreement, the Company expects to release the details of the program and university partner

This new partnership and development program will add to the Company's comprehensive portfolio of intellectual property and further validate the Company's effort to be a frontrunner in the psychedelics and therapeutics space.

Keep reading... Show less

Follow-Up Data From Phase 3 Trial of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age

  • Pfizer-BioNTech vaccine demonstrated 100% efficacy against COVID-19 in longer-term analysis, with no serious safety concerns identified
  • Data will support planned submissions for full regulatory approval of the vaccine in this age group in the U.S. and worldwide

Pfizer Inc. (NYSE:PFE) and BioNTech SE (Nasdaq:BNTX) today announced topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in individuals 12 through 15 years of age. The updated findings from the companies' pivotal Phase 3 trial show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-µg per dose) was 100% effective against COVID-19, measured seven days through over four months after the second dose.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211122005249/en/

Keep reading... Show less

Top News

Related News